8-K

                                 UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT


                        Pursuant to Section 13 or 15(d)
                     of the Securities Exchange Act of 1934


       Date of Report (Date of earliest event reported): September 7, 2005

                                HUMAN BIOSYSTEMS
             (Exact name of registrant as specified in its charter)

                                   000-28413
                            (Commission File Number)

           California                                      77-0481056
 (State or other jurisdiction             (I.R.S. Employer Identification No.)
                       of incorporation or organization)

                    1127 Harker Avenue, Palo Alto, CA 94301
          (Address of Principal Executive Offices Including Zip Code)

       Registrant's telephone number, including area code: (650) 323-0943

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (See General Instruction A.2. below):

[ ]  Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)

[ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

[ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
=======================================================================

Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
Appointment of Principal Officers.

Effective September 7, 2005, Dr. George Tsukuda resigned from Human BioSystems'
Board of Directors.  Dr. Tsukuda, who had served on the Board of Directors since
the Company's inception, resigned in order to pursue other personal and business
interests.

On September 7, 2005, the Board of Directors of Human BioSystems appointed Dr.
Larry McCleary to fill the vacancy created by Dr. Tsukuda's resignation.  Dr.
McCleary has spent the last seven years serving as Director of Human Research
for Advanced Metabolic Research Group, LLC, headquartered in Henderson, NV.  Dr.
McCleary has also been serving on Human BioSystems' Advisory Board since 2002.

There are no transactions between Dr. McCleary and the Company that would
require disclosure under Item 404(a) of Regulation S-B.  Dr. McCleary is not
currently serving on any committee of the Board of Directors.

A copy of the press release announcing the resignation of Dr. Tsukuda and
appointment of Dr. McCleary is attached as Exhibit 99.1 to this Current Report
and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits

(a)	Financial Statements of Business Acquired: Not Applicable
(b)	Pro Forma Financial Information: Not Applicable
(c)	Exhibits: The following exhibits are included as part of this report:

Exhibit No.	Description
- ----------     --------------
99.1		Press Release: Human BioSystems Makes a New Board of
                Directors Appointment

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated: September 12, 2005


HUMAN BIOSYSTEMS

By:/s/ Harry Masuda
- ---------------------
  Harry Masuda
  President and CEO

EX-99.1

Exhibit 99.1

Human BioSystems Makes a New Board of Directors Appointment

PALO ALTO, Calif.--Sept. 7, 2005--Human Biosystems (OTCBB:HBSC - News) announces
today the appointment of Dr. Larry McCleary to its Board of Directors. Dr.
McCleary replaces Dr. George Tsukuda, who served on the Board since the
Company's inception. Dr. Tsukuda has made the decision to pursue other personal
and business interests. "His service over the years has been very much
appreciated for not only his service on the Board of HBS, but also for his
financial support throughout the years, even during very critical times," said
Mr. Masuda, CEO of HBS.

"I am very pleased to welcome Dr. McCleary to our Board," said Harry Masuda.
"His background in medicine as a pediatric neurosurgeon and in business as an
entrepreneur will add diversity and experience to our Board. Dr. McCleary's
service to HBS up to now has included being an active member of our Advisory
Board. He and his wife Christine have also made substantial financial
investments over the years in HBS" continued Mr. Masuda.

Dr. McCleary was formerly Acting Chief of Pediatric Neurosurgery at Denver
Children's Hospital and most currently is the Director of Research at Advanced
Metabolic Research Group.

He is the author of numerous publications in the fields of biotechnology,
neurosurgery and tumor immunology and has been invited to speak at medical
meetings nationally and internationally.

Dr. McCleary was involved in clinical program development at the Denver
Children's Hospital and is the founder of the Children's Neuroscience Research
foundation.

He received his B.A. from Dartmouth College and did his neurosurgery training at
New York University/Bellevue Medical Center.

HBS is headquartered in Palo Alto, California with research facilities in
Michigan.

Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995).
Because such statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Factors that could cause results to differ materially from those
expressed or implied by such forward-looking statements include, but are not
limited to, results from ongoing research and development as well as clinical
studies, failure to obtain regulatory approval for the Company's products, if
required, failure to develop a product based on the Company's technology,
failure of any such products to compete effectively with existing products, the
ability of the Company to fund marketing and sales efforts that may be required
to effectively sell its products .and other factors discussed in filings made by
the Company with the Securities and Exchange Commission.

Human BioSystems (OTC Bulletin Board:HBSC - News)

________________________________________
Contact:
     Human BioSystems
     Harry Masuda
     CEO
     (650) 323-0943
     hmasuda@humanbiosystems.com
     OR
     YES INTERNATIONAL
     Rich Kaiser
     Investor Relations
     (800) 631-8127
     yes@yesinternational.com